Crispr Therapeutics AG vs United Parcel Service Inc — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while United Parcel Service Inc trades at $94.58 (market cap $80.08B). The key difference: United Parcel Service Inc is far larger — about 16.4× Crispr Therapeutics AG's market cap, and United Parcel Service Inc pays a 6.97% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and United Parcel Service Inc for 141 Days on average.
| CRSP | UPS | |
|---|---|---|
Market Cap | $4.88B | $80.08B |
Volume | 2,861,747 | 6,706,833 |
Sector | Health | Industrials |
52-Week High | $74.92 | $120.00 |
52-Week Low | $44.34 | $82.87 |
Typical Hold Time | 77 Days | 141 Days |
Enterprise Value | $3.30B | $104.10B |
Dividend Yield | — | 6.97% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
UPS trades at $94.54, up 2.45% on the day, with a bearish technical signal but strong recent earnings beats. The stock shows a P/E of 17.5 and a 5.08% net income margin, with revenue declining to $88.66B in 2025. Analyst consensus is a Buy with a $118.67 price target, while recent news highlights margin pressures and new e-commerce initiatives like the UPS Secure Commerce platform.
The outlook is mixed: a high dividend yield near 7% and valuation support offer upside potential, but declining revenue, competitive threats from Amazon, and fuel cost headwinds pose risks. Earnings growth from cost-cutting and domestic margin improvement remains the key catalyst for stock performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →